Frequently asked questions (FAQs)

For which conditions is ADCETRIS® (brentuximab vedotin) approved?

ADCETRIS is approved in the following settings:

  • Consolidation therapy in classical Hodgkin lymphoma (HL): Classical HL at high risk of coming back or becoming worse after stem cell transplant (SCT)
  • Relapsed classical Hodgkin lymphoma (HL): Classical HL after stem cell transplant (SCT) fails or after 2 multiagent chemotherapy regimens fail and SCT is not an option
  • Relapsed systemic anaplastic large cell lymphoma (sALCL): sALCL after a multiagent chemotherapy regimen fails

The effectiveness of ADCETRIS in sALCL is based on studies in which patients’ tumors became smaller. The sALCL study was not designed to show whether or not ADCETRIS could help patients live longer or feel better.

What is the most serious safety information I should know about ADCETRIS?

Progressive multifocal leukoencephalopathy (PML) is a rare but serious infection of the brain that can be severely debilitating and even fatal. PML has occurred in patients receiving ADCETRIS. Cases occurred at different times from the start of ADCETRIS therapy, and some occurred within 3 months. Tell your doctor right away if you have any of the following signs or symptoms: changes in mood or usual behavior; confusion, problems in thinking, or loss of memory; changes in vision, speech, or walking; or decreased strength or weakness on one side of the body.


ADCETRIS should not be taken with bleomycin because of possible side effects in the lungs.

What are the other possible serious side effects of ADCETRIS?

ADCETRIS can cause nerve damage, allergic and infusion reactions, blood problems, infections, tumor lysis syndrome, and patients with severe kidney disease should avoid use of ADCETRIS. Additionally, patients with moderate or severe liver disease should also avoid use of ADCETRIS. Other possible serious side effects include liver injury, lung problems, skin problems, gastrointestinal problems and fetal harm. For descriptions of these side effects, please see Important Safety Information, including BOXED WARNING, and read the full Prescribing Information. Talk to your healthcare team if you have questions.

What are the most common side effects of ADCETRIS therapy?

ADCETRIS was studied in a trial with 329 patients with classical HL at high risk of relapse or progression after stem cell transplantation. The most common side effects in patients who received ADCETRIS (167 patients), were a low number of white blood cells, tingling or numbness in the hands or feet, a low number of platelets (which help the blood clot), a low number of red blood cells, an infection in the upper respiratory tract, feeling tired, trouble moving the hands or feet, nausea, cough, and diarrhea.

ADCETRIS was studied by itself in 160 patients in two clinical trials in patients with relapsed classical HL and relapsed sALCL. Across both trials, the most common side effects were a low number of white blood cells, tingling or numbness in the hands or feet, feeling tired, nausea, a low number of red blood cells, an infection in the upper respiratory tract, diarrhea, fever, rash, a low number of platelets (which help the blood clot), cough, and vomiting.

Are there differences between ADCETRIS and traditional chemotherapy?

ADCETRIS is a cancer therapy designed to work differently than traditional chemotherapy. It is designed to target cells that have CD30, which is not commonly found on healthy cells. Even though ADCETRIS is a CD30-directed therapy, it can still harm normal cells and cause side effects. You should discuss potential side effects with your doctor. Also, please read the full Prescribing Information for a complete list of side effects. Click the links to see how ADCETRIS works, for patients with relapsed cHL or relapsed sALCL

How is ADCETRIS given?

ADCETRIS is given as an intravenous (IV) infusion every 3 weeks. Each infusion takes about 30 minutes. If you have mild liver disease, your doctor may give you a lower dose of ADCETRIS. Patients with moderate or severe liver disease or severe kidney disease should avoid using ADCETRIS.

For how long will I be on ADCETRIS therapy?

How long you will be on ADCETRIS therapy will depend on the condition you are being treated for. For consolidation therapy after stem cell transplant in classical HL, ADCETRIS is normally given 4-6 weeks after your transplant, or as soon as your doctor thinks you are ready and may be given for up to 16 doses, until your disease progresses, or there are side effects that outweigh the potential benefits of treatment. For relapsed classical HL and relapsed sALCL, ADCETRIS may be given until your disease progresses or there are side effects that outweigh the potential benefits of treatment. The average length of ADCETRIS therapy varied for each condition it has been studied in.

  • Consolidation therapy in classical HL: the average duration of therapy was 15 cycles, and 48% (n=80) of people received 16 cycles of therapy
  • Relapsed classical HL: 27 weeks
  • Relapsed sALCL: 24 weeks

Speak with your doctor to determine which treatment plan is right for you.

What might cause my dose to be adjusted or stopped?

If you have liver or kidney disease, be sure to notify your healthcare team. If you have mild liver disease, your doctor may give you a lower dose of ADCETRIS. Patients with moderate or severe liver disease or severe kidney disease should avoid using ADCETRIS. Even though ADCETRIS is a CD30-directed therapy, it can still harm normal cells and cause side effects.

Side effects sometimes cause people to stop treatment earlier than planned. Your doctor might need to delay giving you your next dose or give you less ADCETRIS until your symptoms improve. In cases where side effects are severe, or do not improve, you might need to stop taking ADCETRIS completely. It is important to tell your healthcare team as soon as possible about any symptoms that develop.

In 2 studies of 160 people with relapsed classical HL and relapsed sALCL treated with ADCETRIS, 21% of patients stopped treatment with ADCETRIS because of side effects. Adverse reactions that led to stopping therapy in 2 or more people in these 2 studies were peripheral sensory neuropathy (8%) and peripheral motor neuropathy (3%). Adverse reactions that led to dose delays in more than 5% of people in these 2 studies were low white blood cell count (14%) and peripheral sensory neuropathy (11%).

In the study of 167 people treated with ADCETRIS in the consolidation therapy after SCT trial, 32% of people stopped therapy with ADCETRIS because of side effects. Adverse reactions that led to dose delays in more than 5% of people in this trial were low white blood cell counts (22%), peripheral sensory neuropathy (16%), upper respiratory tract infections (6%), and peripheral motor neuropathy (6%).

Will I lose my hair as a result of ADCETRIS therapy?

In 2 studies of 160 people treated with ADCETRIS, 13% of patients with relapsed classical HL and 14% of patients with relapsed sALCL reported some degree of hair loss.

What if I can’t afford my co-pay or don’t have insurance?

Your Oncology Nurse Advocate can help if you don’t have any health insurance, aren’t sure if your insurance will cover your Seattle Genetics treatment, or need co-insurance/copay support* for your treatment costs.

Talk to your doctor about enrolling in SeaGen Secure® or call 855.4SECURE (855.473.2873)

*Copay support is provided through foundation referral.

Please see Important Safety Information, including BOXED WARNING, and read full Prescribing Information.

SAFETY FIRST

Learn More

Want to find some helpful websites and connect to others?

Read more

Learn more about patient services

SeaGen Secure
Important Safety Information
Important Safety Information

Indications

ADCETRIS is approved in the following settings:

  • Relapsed classical Hodgkin lymphoma (HL): Classical HL after a stem cell transplant (SCT) fails or after 2 multiagent chemotherapy regimens fail and SCT is not an option
  • Consolidation therapy in HL: Classical HL at high risk of coming back or becoming worse after SCT
  • Relapsed systemic anaplastic large cell lymphoma (sALCL): sALCL after a multiagent chemotherapy regimen fails

The effectiveness of ADCETRIS in sALCL is based on studies in which patients’ tumors became smaller. The sALCL study was not designed to show whether or not ADCETRIS could help patients live longer or feel better.

Important Safety Information

What is the Most Important Serious Safety Information I Should Know About ADCETRIS® (brentuximab vedotin) for injection?

  • Progressive multifocal leukoencephalopathy (PML): A rare but serious infection of the brain that can lead to death and can occur in ADCETRIS-treated patients. Cases occurred at different times from the start of ADCETRIS therapy, some within 3 months. Possible causes other than ADCETRIS-treatment include previous therapies and diseases that may weaken your immune system.
  • ADCETRIS should not be taken with bleomycin because of possible side effects in the lungs.

What are the Other Possible Serious Side Effects of ADCETRIS?

  • Nerve damage: Peripheral neuropathy (nerve damage) that mostly involves numbness or tingling in the hands or feet (sensory) and/or weakness in the arms or legs (motor). Symptoms increase with more doses. Your doctor may change or stop your ADCETRIS dose depending on the severity of your symptoms.
  • Allergic and infusion reactions: Allergic reactions, including severe forms, during infusion or up to 24 hours after administration of ADCETRIS. Patients who had a reaction with earlier doses should receive premedication with later doses, which may include acetaminophen, an antihistamine, and a corticosteroid.
  • Blood problems: Low number of white blood cells lasting a week or more, with or without fever. Low number of platelets (which help the blood clot) and low number of red blood cells. Your blood counts will be checked before each dose, more often if necessary. You will be monitored for fever. If your white blood cell count is too low, your doctor may delay your next infusion, lower your dose, stop your ADCETRIS therapy, or give you a medicine called growth factor with future doses of ADCETRIS.
  • Infections: Serious infections that occur when your immune system is weakened, such as pneumonia, bacteremia, and sepsis or septic shock (including deaths).
  • Tumor lysis syndrome (TLS): You will be closely monitored for TLS if you have a tumor that grows quickly or have many tumor cells throughout your body.
  • Patients with severe kidney disease: May have more side effects and deaths compared to patients with normal kidney function and should avoid use of ADCETRIS.
  • Patients with moderate or severe liver disease: May have more side effects and deaths compared to patients with normal liver function and should avoid use of ADCETRIS.
  • Liver injury: Liver problems (including deaths) have been reported after the first dose of ADCETRIS and after ADCETRIS was stopped and restarted. Your liver function will be monitored. Having liver problems, raised liver enzymes, and some medicines may increase the risk. Your doctor may delay your next infusion, lower your dose, or stop your ADCETRIS therapy if you have liver problems.
  • Lung problems: Lung problems, including deaths, have been reported. If you have symptoms, your doctor may hold your ADCETRIS therapy until they improve.
  • Skin problems: Rare but serious skin conditions (including deaths) called Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN). If either occurs, your doctor will stop ADCETRIS and treat you for symptoms.
  • Gastrointestinal (GI) problems: Stomach and intestine problems, including deaths, have been reported. Lymphoma that involves the stomach or intestine may increase the risk of GI perforation (hole in the stomach or intestine).
  • Embryo-fetal toxicity: Based on the mechanism of action and animal studies, ADCETRIS can cause fetal harm. Advise females of reproductive potential of the potential risk to the fetus and to avoid pregnancy during, and for at least 6 months after final dose of ADCETRIS.

What Were the Most Common Side Effects in Clinical Trials?

ADCETRIS was studied by itself in 160 patients in two clinical trials in patients with relapsed classical HL and relapsed sALCL. Across both trials, the most common side effects were a low number of white blood cells, tingling or numbness in the hands or feet, feeling tired, nausea, a low number of red blood cells, an infection in the upper respiratory tract, diarrhea, fever, rash, a low number of platelets (which help the blood clot), cough, and vomiting.

ADCETRIS was studied in a trial with 329 patients with classical HL at high risk of relapse or progression after stem cell transplantation. The most common side effects in patients who received ADCETRIS (167 patients), were a low number of white blood cells, tingling or numbness in the hands or feet, a low number of platelets (which help the blood clot), a low number of red blood cells, an infection in the upper respiratory tract, feeling tired, trouble moving the hands or feet, nausea, cough, and diarrhea.

What Should I Tell My Doctor Before I Start Treatment with ADCETRIS?

  • Tell your doctor about all of your medical conditions. ADCETRIS should be avoided if you have severe kidney disease or moderate or severe liver disease or other liver problems.
  • Tell your doctor about any medicine you are taking (including over-the-counter drugs, vitamins, and herbal supplements) because it is possible for ADCETRIS to interact with certain types of drugs.
  • Tell your doctor if you are pregnant or plan to become pregnant. You should not take ADCETRIS while pregnant or breastfeeding.
  • Women should use effective birth control while taking ADCETRIS and for at least 6 months after the final dose of ADCETRIS.
  • Men with female partners should use effective birth control while taking ADCETRIS and for at least 6 months after the final dose of ADCETRIS.

Contact Your Doctor if You Experience Any of the Following:

  • Symptoms of nerve damage: Tingling, burning, or numbness in the hands or feet. Changes in sense of touch or trouble moving the hands or feet.
  • Symptoms of infection: Fever of 100.5° or higher, chills, cough, or pain upon urination.
  • Symptoms of infusion reaction: Fever, chills, rash, or breathing problems within 24 hours of infusion.
  • Symptoms of liver injury: Fatigue, anorexia, upper stomach pain, dark urine, yellowing of the skin and eyes (jaundice).
  • Symptoms of PML: Changes in mood or usual behavior. Confusion, thinking problems, or loss of memory. Changes in vision, speech, or walking. Decreased strength or weakness on one side of the body.
  • Symptoms of pancreatitis: Severe abdominal pain.
  • Symptoms of lung problems: New or worsening cough or shortness of breath.
  • Symptoms of GI problems: Severe stomach pain, chills, fever, nausea, vomiting, or diarrhea.
  • Pregnancy: Pregnant or breastfeeding women should not receive ADCETRIS.
  • Any other side effects that are bothersome or do not go away.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/Safety/MedWatch or call 1-800-FDA-10881-800-FDA-1088.

Please see Important Safety Information, including BOXED WARNING, and read full Prescribing Information.

Important Safety Information
Important Safety Information

Indications

ADCETRIS is approved in the following settings:

  • Relapsed classical Hodgkin lymphoma (HL): Classical HL after a stem cell transplant (SCT) fails or after 2 multiagent chemotherapy regimens fail and SCT is not an option
  • Consolidation therapy in HL: Classical HL at high risk of coming back or becoming worse after SCT
  • Relapsed systemic anaplastic large cell lymphoma (sALCL): sALCL after a multiagent chemotherapy regimen fails

The effectiveness of ADCETRIS in sALCL is based on studies in which patients’ tumors became smaller. The sALCL study was not designed to show whether or not ADCETRIS could help patients live longer or feel better.

Important Safety Information

What is the Most Important Serious Safety Information I Should Know About ADCETRIS® (brentuximab vedotin) for injection?

  • Progressive multifocal leukoencephalopathy (PML): A rare but serious infection of the brain that can lead to death and can occur in ADCETRIS-treated patients. Cases occurred at different times from the start of ADCETRIS therapy, some within 3 months. Possible causes other than ADCETRIS-treatment include previous therapies and diseases that may weaken your immune system.
  • ADCETRIS should not be taken with bleomycin because of possible side effects in the lungs.

What are the Other Possible Serious Side Effects of ADCETRIS?

  • Nerve damage: Peripheral neuropathy (nerve damage) that mostly involves numbness or tingling in the hands or feet (sensory) and/or weakness in the arms or legs (motor). Symptoms increase with more doses. Your doctor may change or stop your ADCETRIS dose depending on the severity of your symptoms.
  • Allergic and infusion reactions: Allergic reactions, including severe forms, during infusion or up to 24 hours after administration of ADCETRIS. Patients who had a reaction with earlier doses should receive premedication with later doses, which may include acetaminophen, an antihistamine, and a corticosteroid.
  • Blood problems: Low number of white blood cells lasting a week or more, with or without fever. Low number of platelets (which help the blood clot) and low number of red blood cells. Your blood counts will be checked before each dose, more often if necessary. You will be monitored for fever. If your white blood cell count is too low, your doctor may delay your next infusion, lower your dose, stop your ADCETRIS therapy, or give you a medicine called growth factor with future doses of ADCETRIS.
  • Infections: Serious infections that occur when your immune system is weakened, such as pneumonia, bacteremia, and sepsis or septic shock (including deaths).
  • Tumor lysis syndrome (TLS): You will be closely monitored for TLS if you have a tumor that grows quickly or have many tumor cells throughout your body.
  • Patients with severe kidney disease: May have more side effects and deaths compared to patients with normal kidney function and should avoid use of ADCETRIS.
  • Patients with moderate or severe liver disease: May have more side effects and deaths compared to patients with normal liver function and should avoid use of ADCETRIS.
  • Liver injury: Liver problems (including deaths) have been reported after the first dose of ADCETRIS and after ADCETRIS was stopped and restarted. Your liver function will be monitored. Having liver problems, raised liver enzymes, and some medicines may increase the risk. Your doctor may delay your next infusion, lower your dose, or stop your ADCETRIS therapy if you have liver problems.
  • Lung problems: Lung problems, including deaths, have been reported. If you have symptoms, your doctor may hold your ADCETRIS therapy until they improve.
  • Skin problems: Rare but serious skin conditions (including deaths) called Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN). If either occurs, your doctor will stop ADCETRIS and treat you for symptoms.
  • Gastrointestinal (GI) problems: Stomach and intestine problems, including deaths, have been reported. Lymphoma that involves the stomach or intestine may increase the risk of GI perforation (hole in the stomach or intestine).
  • Embryo-fetal toxicity: Based on the mechanism of action and animal studies, ADCETRIS can cause fetal harm. Advise females of reproductive potential of the potential risk to the fetus and to avoid pregnancy during, and for at least 6 months after final dose of ADCETRIS.

What Were the Most Common Side Effects in Clinical Trials?

ADCETRIS was studied by itself in 160 patients in two clinical trials in patients with relapsed classical HL and relapsed sALCL. Across both trials, the most common side effects were a low number of white blood cells, tingling or numbness in the hands or feet, feeling tired, nausea, a low number of red blood cells, an infection in the upper respiratory tract, diarrhea, fever, rash, a low number of platelets (which help the blood clot), cough, and vomiting.

ADCETRIS was studied in a trial with 329 patients with classical HL at high risk of relapse or progression after stem cell transplantation. The most common side effects in patients who received ADCETRIS (167 patients), were a low number of white blood cells, tingling or numbness in the hands or feet, a low number of platelets (which help the blood clot), a low number of red blood cells, an infection in the upper respiratory tract, feeling tired, trouble moving the hands or feet, nausea, cough, and diarrhea.

What Should I Tell My Doctor Before I Start Treatment with ADCETRIS?

  • Tell your doctor about all of your medical conditions. ADCETRIS should be avoided if you have severe kidney disease or moderate or severe liver disease or other liver problems.
  • Tell your doctor about any medicine you are taking (including over-the-counter drugs, vitamins, and herbal supplements) because it is possible for ADCETRIS to interact with certain types of drugs.
  • Tell your doctor if you are pregnant or plan to become pregnant. You should not take ADCETRIS while pregnant or breastfeeding.
  • Women should use effective birth control while taking ADCETRIS and for at least 6 months after the final dose of ADCETRIS.
  • Men with female partners should use effective birth control while taking ADCETRIS and for at least 6 months after the final dose of ADCETRIS.

Contact Your Doctor if You Experience Any of the Following:

  • Symptoms of nerve damage: Tingling, burning, or numbness in the hands or feet. Changes in sense of touch or trouble moving the hands or feet.
  • Symptoms of infection: Fever of 100.5° or higher, chills, cough, or pain upon urination.
  • Symptoms of infusion reaction: Fever, chills, rash, or breathing problems within 24 hours of infusion.
  • Symptoms of liver injury: Fatigue, anorexia, upper stomach pain, dark urine, yellowing of the skin and eyes (jaundice).
  • Symptoms of PML: Changes in mood or usual behavior. Confusion, thinking problems, or loss of memory. Changes in vision, speech, or walking. Decreased strength or weakness on one side of the body.
  • Symptoms of pancreatitis: Severe abdominal pain.
  • Symptoms of lung problems: New or worsening cough or shortness of breath.
  • Symptoms of GI problems: Severe stomach pain, chills, fever, nausea, vomiting, or diarrhea.
  • Pregnancy: Pregnant or breastfeeding women should not receive ADCETRIS.
  • Any other side effects that are bothersome or do not go away.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/Safety/MedWatch or call 1-800-FDA-10881-800-FDA-1088.